In people with NAFLD, interventions aimed at weight loss were associated with statistically and clinically significant improvements in blood biomarkers of liver disease, such as ALT and AST, as well as radiologic and histologic markers, such as liver stiffness, steatosis, and the NAS. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.